Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Atea Pharmaceuticals, Inc. (AVIR : NSDQ)

• Company Description    Atea Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections. Atea Pharmaceuticals Inc. is based in BOSTON. Number of Employees: 56

• Price / Volume Information    Yesterday's Closing Price: $3.11 Daily Weekly Monthly 20 Day Moving Average: 428,187 shares Shares Outstanding: 79.36 (millions) Market Capitalization: $246.80 (millions) Beta: 0.22 52 Week High: $4.02 52 Week Low: $2.46 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 2.30% 1.70% 12 Week -9.33% -14.09% Year To Date -7.16% -17.95%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 225 Franklin Street Suite 2100 - BOSTON,MA 02110 USA ph: 857-284-8891 fax: - investors@ateapharma.com http://www.ateapharma.com

• General Corporate Information    Officers Jean-Pierre Sommadossi - President; Chief Executive Officer and Chairman Andrea Corcoran - Chief Financial Officer and Executive Vice Preside Wayne Foster - Executive Vice President; Chief Accounting Officer Franklin Berger - Director Jerome Adams - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 04683R106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/06/25 Share - Related Items Shares Outstanding: 79.36 Most Recent Split Date: (:1) Beta: 0.22 Market Capitalization: $246.80 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.48 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.78 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.73 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 8.33% vs. Previous Quarter: -10.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - -32.55 03/31/25 - -31.26 ROA 09/30/25 - - 06/30/25 - -30.47 03/31/25 - -29.27 Current Ratio 09/30/25 - - 06/30/25 - 19.17 03/31/25 - 19.94 Quick Ratio 09/30/25 - - 06/30/25 - 19.17 03/31/25 - 19.94 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - 4.26 03/31/25 - 4.80 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©